Japan's Ministry of Health, Labor and Welfare has approved Takeda's NDA for cell-cultured flu vaccine, using Baxter International's technology.
This week, a number of news sources reported that Japan's Ministry of Health,Labor and Welfare has approved Takeda International's NDA for cell-cultured influenza vaccine. Pharmaceutical Business Review
reported on April 1 that the vaccine will be made at a new facility at Takeda's Hikan manufacturing complex in Yamaguchi Prefecture. The company will reportedly use technology that it licensed from Baxter International, and which the two companies have been jointly developing since 2010.